# Project Title: Computational Drug Discovery

## Table of Contents
1. [Introduction](#introduction)
2. [Data Preprocessing](#data-preprocessing)
3. [Exploratory Data Analysis (EDA)](#eda)
4. [Model Building](#model-building)


## 1. Introduction <a name="introduction"></a>
In recent years, computational methods have emerged as indispensable tools in the field of drug discovery, offering unprecedented opportunities to expedite the identification and development of novel therapeutic agents. This project seeks to harness the power of machine learning and computational biology to predict the biological activity of chemical compounds, with a particular focus on targeting the protein Acetylcholinesterase (AChE) and its significance in Alzheimer's disease treatment.

### Objectives and Scope:
The primary objective of this project is to develop predictive models that can accurately forecast the biological activity of compounds targeting AChE. By leveraging machine learning algorithms and molecular descriptors, we aim to identify potential drug candidates with inhibitory activity against AChE, paving the way for the discovery of new treatments for Alzheimer's disease. The scope of the project encompasses data collection, preprocessing, model building, and evaluation, with a focus on translating computational insights into actionable strategies for drug discovery research.

### Importance of Predicting Biological Activity:
Predicting the biological activity of chemical compounds is a crucial step in the drug discovery process, as it allows researchers to prioritize and prioritize candidate molecules for further experimental validation. AChE, a key enzyme involved in neurotransmission, has been implicated in the pathogenesis of Alzheimer's disease, making it an attractive target for therapeutic intervention. By accurately predicting the biological activity of compounds targeting AChE, we can expedite the drug discovery process, potentially leading to the development of more effective treatments for Alzheimer's disease and other neurological disorders.

## 2. Data Preprocessing <a name="data-preprocessing"></a>
Description of the ChEMBL Database:
The ChEMBL database serves as a comprehensive repository of bioactivity data, primarily focusing on small molecules and their interactions with biological targets. It contains curated information from scientific literature, patents, and other public sources, making it invaluable for drug discovery research. The dataset includes compound-target interactions, such as binding affinities and inhibition constants, along with molecular properties and descriptors.

Retrieving Data for Compounds Targeting AChE:
Biological activity data for compounds targeting AChE were retrieved from the ChEMBL database using the chembl_webresource_client Python library. Queries were performed based on keywords such as "Acetylcholinesterase" or "AChE" as the target protein, extracting data on compound bioactivity, particularly potency measurements like IC50 values.

Data Preprocessing Steps:
Initial data retrieval from ChEMBL database.
Handling missing values: Removing compounds with missing values for key columns like 'standard_value' and 'canonical_smiles'.
Data deduplication: Removing duplicate compounds based on canonical smiles.
Labeling compounds: Categorizing compounds as active, inactive, or intermediate based on their potency values.
Saving preprocessed data to CSV files for further analysis.

## 3. Exploratory Data Analysis (EDA) <a name="eda"></a>
Calculating Lipinski Descriptors:
Lipinski's Rule-of-Five provides guidelines for assessing the drug-likeness of compounds based on key molecular properties. These properties include molecular weight, LogP (partition coefficient), hydrogen bond donors, and acceptors. Calculating Lipinski descriptors allows filtering and prioritization of compounds with favorable pharmacokinetic profiles, essential for oral bioavailability and efficacy.

Statistical Analysis and Visualization:
EDA involves statistical analysis and visualization of compound properties, such as molecular weight (MW), LogP, number of hydrogen bond donors, and acceptors. Box plots and scatter plots are used to explore the distribution and relationship of these properties across different bioactivity classes. Statistical tests like Mann-Whitney U test are performed to assess significant differences between active and inactive compounds.

Summary and Insights:
Exploratory data analysis provides insights into the distribution of compound properties and their association with bioactivity classes. This information guides further analysis and model development for predicting compound activity against AChE, contributing to the drug discovery process.



## 4. Model Building <a name="model-building"></a>

### Machine Learning Models for Predicting Biological Activity:
The model building phase aims to develop predictive models capable of forecasting the biological activity of compounds targeting Acetylcholinesterase (AChE). Various machine learning algorithms, such as Random Forest, Support Vector Machines (SVM), and Neural Networks, can be explored to build these models. The process involves the following steps:

1. **Feature Engineering:** Extracting relevant features from molecular descriptors and compound properties obtained during data preprocessing. These features serve as input variables for the predictive models.

2. **Model Selection:** Evaluating different machine learning algorithms to determine the most suitable model for predicting compound activity against AChE. Model selection criteria include performance metrics such as accuracy, precision, recall, and area under the receiver operating characteristic curve (AUC-ROC).

3. **Model Training:** Training the selected machine learning model on the preprocessed dataset, using techniques like cross-validation to optimize model parameters and prevent overfitting.

4. **Model Evaluation:** Assessing the performance of the trained model using test data to validate its predictive accuracy and generalization capabilities. Performance metrics and visualization techniques, such as confusion matrices and ROC curves, aid in evaluating model performance.

5. **Model Interpretation:** Analyzing the trained model to understand the importance of different features and their contribution to predicting compound activity. Interpretability of the model helps in gaining insights into the underlying biological mechanisms and guiding further drug discovery research.

### Integration and Deployment:
Once a satisfactory predictive model is developed, it can be integrated into drug discovery pipelines for screening large compound libraries and identifying potential drug candidates. Deployment of the model as part of a computational toolkit enables researchers to expedite the process of identifying lead compounds with therapeutic potential.

### Iterative Model Refinement:
Model building is an iterative process, often involving multiple iterations of feature engineering, model selection, and evaluation. Continuous refinement of the predictive models based on new data and insights improves their accuracy and reliability, enhancing their utility in drug discovery research.


...
